Loading clinical trials...

Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples | Clinical Trials | Clareo Health

RECRUITINGNA

Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples

NCT06307977•Hunter College of City University of New York

View on ClinicalTrials.gov

Summary

This study utilizes a randomized controlled trial design to evaluate the efficacy of couples motivational interviewing (MI) to reduce the frequency and severity of illicit drug use and frequency of HIV transmission risk behavior (TRB). Participants are randomized to one of two conditions: couples MI or standard couples HIV testing and counseling (CHTC).

Eligibility

Age

18 - 55 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Have a main partner who is another cisgender male and have been in a relationship for 3 month or longer
•Index participant must be between 18 and 55; Main partner can be any age 18 and older
•One participant must be HIV negative (as confirmed by rapid test)
•One participant must have used at least 1 drug in the past 30 days (cocaine/crack, opiates, misuse of prescription medication, stimulants, psychedelics, ecstasy, ketamine, GHB, amyl nitrite)
•Index participant must have engaged in TRB in the past 30 days- Defined as CAS with a casual partner, or a serodiscordant or non-monogamous main partner
•Live in the United States
•Speak and read English

Exclusion Criteria

•Any signs of serious mental illness or cognitive deficit
•Current suicidal/homicidal ideations
•History of IPV with their main partner and safety concerns in the current relationship.

Locations (3)

Wayne State University

Detroit, Michigan, United States

Hunter College

New York, New York, United States

University of Virginia

Charlottesville, Virginia, United States

Key Dates

Start Date

May 25, 2024

Primary Completion Date

January 1, 2028

Completion Date

February 1, 2029

Last Updated

June 13, 2025

Enrollment

360

ESTIMATED participants

Conditions

Substance UseHIV Infections

Interventions

Couples Health Project

BEHAVIORAL

Contacts

Tyrel J Starks, PHD

CONTACT

212-206-7919 tstarks@hunter.cuny.edu

Demetria Cain, PHD

CONTACT

212-206-7919 dcain@prideresearch.org

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921

Opioid-use DisorderSubstance Use Disorders

View study

RECRUITINGPHASE4

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335

HIVSubstance Use Disorder (SUD)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples

Inclusion Criteria

Exclusion Criteria

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Primary Connections for Youth and Families

Gii'Igoshimong: Sitting With Your First Family

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals